RTW Investments LP Invests $3.88 Million in CeriBell (NASDAQ:CBLL)

RTW Investments LP acquired a new position in CeriBell (NASDAQ:CBLL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $3,882,000. RTW Investments LP owned 0.42% of CeriBell as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. FMR LLC acquired a new stake in CeriBell in the fourth quarter worth about $128,120,000. Red Tree Management LLC acquired a new stake in CeriBell in the 4th quarter valued at about $57,083,000. ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in shares of CeriBell during the 4th quarter valued at about $28,160,000. RA Capital Management L.P. bought a new position in shares of CeriBell during the 4th quarter valued at about $21,340,000. Finally, Vanguard Group Inc. bought a new position in shares of CeriBell during the 4th quarter valued at about $18,015,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on CBLL. Canaccord Genuity Group restated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a research note on Friday, April 4th. They set a “buy” rating and a $32.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $32.50.

CeriBell Stock Up 6.9%

NASDAQ CBLL opened at $17.59 on Friday. The stock has a 50 day moving average of $17.61. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analysts’ expectations of $19.30 million. Sell-side analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Transactions at CeriBell

In related news, CEO Xingjuan Chao sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the transaction, the chief executive officer now owns 746,451 shares of the company’s stock, valued at approximately $11,211,694.02. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 24,700 shares of company stock valued at $372,434 over the last three months.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.